finasteride Articles
US Drug Majors See 2nd-Half Double-Digit Growth
29 July 1996
Merck's New Drugs For Arthritis And Infections
27 May 1996
VA Study Rates Hytrin Over Proscar
13 May 1996
US Drug Lag Does Not Exist, Claims FDA Study
15 January 1996
US Drug Cos Reveal Strong Growth In 1995 3rd Qtr
30 October 1995
Proscar Versus Hytrin And Cardura For BPH
11 September 1995
The ABPI's A-Z Of British Medicines Research
29 May 1995
Pfizer's Cardura Approved For BPH
13 February 1995
Benefits From PBM/MPC Acquisitions Assessed
15 August 1994
First Release Of Long-Term Proscar Data
25 July 1994
PH II RESULTS OF PROSCAR BALDNESS TRIALS
25 April 1994
MERCK & CO POSTS 10% PR0FIT RISE
25 April 1994
WINNERS AND LOSERS IN GLOBAL PHARMA INDUSTRY
31 January 1994
DRUGMAKERS IN ITALY PANIC ON NEW SALES FEARS
10 January 1994
MERCK OFFERS GUARANTEE WITH PROSCAR
10 January 1994
NEW YORK STOCK COMMENT
15 November 1993
US PRODUCT NEWS IN BRIEF
25 October 1993
PROSCAR IN CANCER PREVENTION TRIAL
25 October 1993
ABBOTT'S HYTRIN GETS BPH APPROVAL IN USA
11 October 1993
FUJISAWA FILES NDA FOR PROGRAF
13 September 1993
MARKHAM RESIGNS FROM MERCK & CO
19 July 1993
US DRUGMAKERS AND "THE BLACK HOLE"
21 June 1993
MURPHY'S LAW PERVADES US DRUG STOCKS
17 May 1993
SMITHKLINE BEECHAM "EXCELLENT PROGRESS"
26 April 1993
ABBOTT ACHIEVES RECORD SALES
19 April 1993
SMITHKLINE BEECHAM LICENSES THREE DRUGS
5 April 1993
FDA PANEL BACKS ABBOTT'S HYTRIN
15 March 1993
MERCK CANADA MOVES TO WARD OFF COMPETITION
1 March 1993
NEW YORK STOCK COMMENT
8 February 1993
RECORD RESULTS FROM US PHARMA MAJORS
1 February 1993
NEW CHEMICAL ENTITIES LAUNCHED IN 1992
1 February 1993
FDA APPROVES 26 NEWDRUGS IN 1992
25 January 1993
COMPARATIVE STUDY OF BPH TREATMENTS
18 January 1993
MERCK & CO EARNINGS ESTIMATES LOWERED
14 December 1992
NEW YORK STOCK COMMENT
2 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
NEW YORK STOCK COMMENT
7 September 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
US PRICE MODERATION "VARIES BY COMPANY"
3 August 1992
US APPROVAL FOR MERCK'S PROSTATE DRUG
29 June 1992
LICENSING DEAL FOR LISINOPRIL PRODUCTS
22 June 1992
MERCK'S PROSCAR GETS 2nd APPROVAL
8 June 1992
OTHER USES FOR MERCK'S PROSCAR
18 May 1992
GOOD SALES GROWTH FOR MAJOR US COS IN 1st QTR
27 April 1992
STOCK MARKET COMMENTARY: NEW YORK
10 February 1992
MERCK'S PROSCAR NEARING US APPROVAL
10 February 1992
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
